Insiders at Hillman Solutions selling shares without corresponding purchases may suggest they believe the shares are not undervalued. The significant but not outstanding insider ownership indicates a cautious outlook for the stock.
Hillman Solutions is undervalued, presenting a potential opportunity to buy more HLMN stock. Its future outlook isn't fully reflected in the current price. Consider other factors like balance sheet strength before investing.
Hillman Solutions insiders have shown optimism, refraining from selling shares but making substantial purchases, even at prices higher than current. Their actions indicate confidence in the company's future, despite no recent trades.
Gainers: •$Antares Pharma(ATRS.US)$+48.7% (to be acquired by Halozyme (HALO) for $5.60 per share) •$Sierra Oncology(SRRA.US)$+37.9% (acquired by GSK for $55 per share) •$Amryt Pharma(AMYT.US)$+11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients) •$ブリアセル セラピューティクス(BCTX.US)$+6% (presents development details of...
ヒルマン ソリューションズ Aに関するコメント
• $フォーティネット(FTNT.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $350 (from $325)
• $マイクロチップ テクノロジー(MCHP.US)$ : Stifel Upgrades to Buy from Hold - PT $75 (from $70)
• $オビンティブ(OVV.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $64 (from $56)
• $ライオット プラットフォームズ(RIOT.US)$ : Compass Point Upgrades to Buy from Neutral - PT $14 (from $30)
• $スノーフレイク A(SNOW.US)$ : Jefferies Upgrades to Buy f...
• $アメリカン航空(AAL.US)$ : JP Morgan Upgrades to Neutral From Underweight - PT $26 (from $18)
• $AZEK Co Inc/The(AZEK.US)$ : Citigroup Upgrades to Buy from Neutral - PT $30 (from $36)
• $ボストン・プロパティーズ(BXP.US)$ : Mizuho Upgrades to Buy from Neutral - PT $135 (from $120)
• $ダウ(DOW.US)$ : Citigroup Upgrades To Buy From Neutral - PT $82 (from $70)
• $クローガー(KR.US)$ : Exane Upgrades to Neutral from Underperform - PT $60
• $マイルストーン ファーマシューティカルズ(MIST.US)$ : Piper S...
• $Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $ブリアセル セラピューティクス(BCTX.US)$ +6% (presents development details of...
まだコメントはありません